Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS 9	JUL 27	CA/CAplus enhanced with new citing references
NEWS 10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS 11	JUL 21	USGENE adds bibliographic and sequence information
NEWS 12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS 13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14	AUG 08	Improve STN by completing a survey and be entered to win a gift card
NEWS 15	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

****
* *

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:46:53 ON 15 AUG 2009

=> FIL REG
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 12:47:13 ON 15 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 AUG 2009 HIGHEST RN 1174374-85-6
DICTIONARY FILE UPDATES: 14 AUG 2009 HIGHEST RN 1174374-85-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10541429\pyrrole and indole amides.str



chain nodes :

6 7 8 9 10 11
ring nodes :
1 2 3 4 5
chain bonds :
1-11 4-6 5-10 6-7 7-8 7-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-11 2-3 3-4 4-5 5-10 7-8 7-9
exact bonds :
4-6 6-7

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\STNEXP\Queries\10541429\pyrrole amides.str





chain nodes :
6 7 8 9 10 11 12 13
ring nodes :

```
1  2  3  4  5
chain bonds :
1-10  2-11  3-12  4-13  5-6  6-7  7-8  7-9
ring bonds :
1-2  1-5  2-3  3-4  4-5
exact/norm bonds :
1-2  1-5  1-10  2-3  3-4  4-5  7-8  7-9
exact bonds :
2-11  3-12  4-13  5-6  6-7

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:CLASS  11:CLASS  12:CLASS  13:CLASS



L2      STRUCTURE UPLOADED

=> D
L2 HAS NO ANSWERS
L2                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> S L2
SAMPLE SEARCH INITIATED 12:47:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       72 TO ITERATE

100.0% PROCESSED       72 ITERATIONS                                 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          931 TO     1949
PROJECTED ANSWERS:               4 TO      200

L3            4 SEA SSS SAM L2

=> S L2 FULL
FULL SEARCH INITIATED 12:47:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1187 TO ITERATE

100.0% PROCESSED     1187 ITERATIONS                                76 ANSWERS
SEARCH TIME: 00.00.01
```

```
L4           76 SEA SSS FUL L2

=> S L1
SAMPLE SEARCH INITIATED 12:47:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5606 TO ITERATE

 35.7% PROCESSED     2000 ITERATIONS                              33 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       107630 TO   116610
PROJECTED ANSWERS:            1272 TO     2426

L5           33 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 12:47:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   110160 TO ITERATE

100.0% PROCESSED   110160 ITERATIONS                          1791 ANSWERS
SEARCH TIME: 00.00.01

L6         1791 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              371.28     371.50

FILE 'CAPLUS' ENTERED AT 12:48:00 ON 15 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Aug 2009  VOL 151 ISS 8
FILE LAST UPDATED: 14 Aug 2009  (20090814/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:
```

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

```
=> S L6
L7          377 L6

=> S L4
L8           96 L4

=> S L7 OR L8
L9          451 L7 OR L8

=> S L9 AND INFLAMMAT
=> S L9 AND INFLAMMATION
        216782 INFLAMMATION
L10         167 L9 AND INFLAMMATION

=> S L9 AND INFLAMMATORY
        236860 INFLAMMATORY
L11         179 L9 AND INFLAMMATORY

=> S L10 OR L11
L12         240 L10 OR L11

=> S L12 AND INTERLEUKIN
        199656 INTERLEUKIN
L13           7 L12 AND INTERLEUKIN

=> D IBIB ABS HITSTR TOT
```

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1090523 CAPLUS
DOCUMENT NUMBER: 147:398668
TITLE: Use of gelsolin to diagnose and treat inflammatory diseases
INVENTOR(S): Stossel, Thomas P.; Magnusson Osborn, Anna Charlotta Teresia; Tarkowski, Andrej
PATENT ASSIGNEE(S): The Brigham Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109056	A2	20070927	WO 2007-US6451	20070315
WO 2007109056	A3	20071206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007227613	A1	20070927	AU 2007-227613	20070315
EP 2001496	A2	20081217	EP 2007-753102	20070315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2009004966	A	20090112	KR 2008-725043	20081014
CN 101443030	A	20090527	CN 2007-80017558	20081114
PRIORITY APPLN. INFO.:			US 2006-782508P P	20060315
			WO 2007-US6451 W	20070315

AB The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).
IT 57645-05-3, Sermetacin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of gelsolin to diagnose and treat inflammatory diseases)
RN 57645-05-3 CAPLUS
CN L-Serine, N-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:201135 CAPLUS
DOCUMENT NUMBER: 146:266827
TITLE: Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
INVENTOR(S): O'Connor, James Patrick
PATENT ASSIGNEE(S): Accelalox, Inc., USA
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007022427	A2	20070222	WO 2006-US32367	20060818
WO 2007022427	A3	20070830		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006279325	A1	20070222	AU 2006-279325	20060818
CA 2619608	A1	20070222	CA 2006-2619608	20060818
EP 1947942	A2	20080730	EP 2006-801878	20060818
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009504776	T	20090205	JP 2008-527172	20060818
CN 101277614	A	20081001	CN 2006-80036641	20080402
US 20080280826	A1	20081113	US 2008-995529	20080714
PRIORITY APPLN. INFO.:			US 2005-709838P P	20050818
			WO 2006-US32367 W	20060818

AB Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5- lipoxygenase inhibitors including small interfering RNA (siRNA). These mols. can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain. Administration of 5-lipoxygenase inhibitors nordihydroguaiaretic acid and AA-861 to rats with closed femur fractures resulted in accelerated fracture healing with enhancement of the bone mech. properties.
IT 164083-84-5, Ly311727
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(arachidonic acid metabolic or signaling pathway modulators for bone healing)
RN 164083-84-5 CAPLUS
CN Phosphonic acid, P-[3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]propyl]- (CA INDEX NAME)



L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:675710 CAPLUS
DOCUMENT NUMBER: 141:190512
TITLE: A preparation of 2-arylacetic acid derivatives, useful

for the treatment of IL-8 mediated diseases
INVENTOR(S): Morisseau, Alessio; Allegretti, Marcello; Bertini, Riccardo; Costa, Maria Candida; Bizzarri, Cinzia; Colotta, Francesco
PATENT ASSIGNEE(S): Dompe' S.p.A., Italy
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004090782	A2	20040819	WO 2004-EP1021	20040204
WO 2004090782	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230852	A1	20040819	AU 2004-230852	20040204
CA 2511582	A1	20040819	CA 2004-2511582	20040204
EP 1593314	A2	20051102	EP 2004-707926	20040204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1768026	A	20060503	CN 2004-80008741	20040204
JP 2006516592	T	20060706	JP 2006-501731	20040204
NO 2156897	C2	20090527	NO 2005-127777	20040204
US 20060223842	A1	20061005	US 2005-541429	20050705
NO 20050404017	A	20050930	NO 2005-4017	20050830

PRIORITY APPLN. INFO.: EP 2003-2716 A 20030206
WO 2004-EP1021 W 20040204

OTHER SOURCE(S): MARPAT 141:190512
GI

I

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 740839-28-5 CAPLUS
CN Glycine, N-[(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 740839-29-6 CAPLUS
CN L-Alanine, N-[(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 740839-30-9 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-acetyl-N-[3-(dimethylamino)propyl]-1-methyl- (CA INDEX NAME)



RN 740839-31-0 CAPLUS
CN L-Serine, N-[(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl]-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB The invention relates to a preparation of 2-arylacetic acid derivs. of formula

A-CHRC(O)-Y [wherein A is a 5 to 6 membered (hetero)aromatic ring where heteroatom is selected from N, O, S, etc.; the 5-6 membered (hetero)aromatic

ring is optionally fused with a second ring; Y is NHL, NH-(cyclo)alkyl, or

NH-cycloalkenyl, etc.], useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compds. are used for the prevention and treatment of pathologies deriving from said activation. In particular, o-substituted arylacetic acid derivs., such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, or

melanoma, etc. For instance, prepared in the example 2 acetic acid derivative I

(ID-NH) showed 62% (IL-8) and 5% (GRO-α) inhibitory activity on CXCR1 and CXCR2 receptors.

IT 26235-67-8P 740839-27-4P 740839-28-5P
740839-29-6P 740839-30-9P 740839-31-0P
740839-36-5P 740839-38-7P 740839-39-8P
740839-40-1P 740839-41-2P 740839-42-3P
740839-45-6P 740839-48-9P 740839-56-9P
740839-57-0P

RL: PAC (Pharmacological activity); SPH (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylacetic acids useful for the treatment of IL-8 mediated diseases)

RN 26235-67-8 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-1-methyl- (CA INDEX NAME)



RN 740839-27-4 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-acetyl-1-methyl- (CA INDEX NAME)

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 740839-36-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-benzoyl-N-[3-(dimethylamino)propyl]-2-methyl- (CA INDEX NAME)



RN 740839-38-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 1-benzoyl-N-(2-methoxyethyl)-2-methyl- (CA INDEX NAME)



RN 740839-39-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 1-benzoyl-2-chloro-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 740839-40-1 CAPLUS
CN 1H-Pyrrole-2-acetamide, 1-methyl-5-(2-methyl-1-oxopropyl)- (CA INDEX NAME)

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 740839-41-2 CAPLUS
CN Glycine, N-[5-benzoyl-1-methyl-1H-pyrrol-2-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 740839-42-3 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-N-[2-(2-hydroxyethoxy)ethyl]-1-methyl- (CA INDEX NAME)

RN 740839-45-6 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-acetyl-1-methyl-N-(methylsulfonyl)- (CA INDEX NAME)



RN 740839-48-9 CAPLUS
CN 1H-Pyrrole-2-acetamide, 1-methyl-5-(4-methylbenzoyl)-N-(methylsulfonyl)- (CA INDEX NAME)

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 740839-56-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-2-methyl- (CA INDEX NAME)



RN 740839-57-0 CAPLUS
CN 1H-Indole-3-acetamide, 1-benzoyl-2-methyl- (CA INDEX NAME)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:61490 CAPLUS
DOCUMENT NUMBER: 140:121631
TITLE: Preparation of non-steroidal macrolide erythromycin analog glycosides for treatment of inflammatory diseases
INVENTOR(S): Mersep, Mladen; Mesic, Milan; Tomaskovic, Linda; Markovic, Stribor
PATENT ASSIGNEE(S): Pliva D.D., Croatia
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005309	A2	20040115	WO 2003-HR35	20030707
WO 2004005309	A3	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489398	A1	20040115	CA 2003-2489398	20030707
AU 2003235843	A1	20040123	AU 2003-235843	20030707
US 20040097434	A1	20040520	US 2003-615010	20030707
US 7108376	B2	20060919		
BR 2003012584	A	20050412	BR 2003-12584	20030707
EP 1521763	A2	20050413	EP 2003-762824	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665825	A	20050907	CN 2003-816092	20030707
CN 100417659	C	20080910		
JP 2005534648	T	20051117	JP 2004-519020	20030707
NZ 537714	A	20070330	NZ 2003-537714	20030707
NO 2043998	C2	20081027	NO 2005-103327	20030707
NO 2005005571	A	20050331	NO 2005-571	20050202
NO 326965	A1	20090529	NO 2006-100928	20060120
PRIORITY APPLN. INFO.:			US 2002-394671P	P 20020708
			WO 2003-HR35	W 20030707

OTHER SOURCE(S): MARPAT 140:121631
OI

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB The present invention relates (a) to new compds. represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, (b) to their pharmacol. acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. The present invention relates (a) to new compds. represented by the formula M-L-D; wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a nonsteroidal subunit (nonsteroidal moiety) derived from nonsteroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID); and L represents a linking group covalently linking M and D; (b) to their pharmacol. acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Such compds. inhibit many cytokines and immune mediators involved in immune responses which cause inflammation, allergy, or allo-immunity, including without limitation IL-1, ICAM, and TNF-α. Thus, title I was prepared and tested as anti-inflammatory agent.

IT 643017-05-4P 643017-09-8P 643017-10-1P
643017-12-3P 643017-19-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study), PREP (Preparation); USES (Uses)
(preparation of steroid-containing macrolide erythromycin analog glycosides for

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Continued)



PAGE 1-A

PAGE 1-B

RN 643017-69-8 CAPLUS
CN 1H-Indole-3-acetamide, 1-[4-chlorobenzoyl]-N-[3-[[2R,3S,4R,5S,8R,10R,11R,12S,13S,14R]-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(ethylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-6-oxa-6-azacyclopentadec-9-yl]propyl]-5-methoxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A



PAGE 1-B

RN 643017-70-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecane-7,15-dione, 13-[[4-C-[[[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino]ethyl]amino]methyl]-2,6-dideoxy-3-C-methyl-3-O-methyl-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4-dihydroxy-10-methoxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(ethylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A

PAGE 1-B

RN 643017-12-3 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 12-[[4-O-[3-[[[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino]ethyl]amino]-1-oxopropyl]-2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-A

PAGE 1-B

RN 643017-10-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecane-7,15-dione, 13-[[4-C-[[[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino]ethyl]amino]methyl]-2,6-dideoxy-3-C-methyl-3-O-methyl-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4-dihydroxy-10-methoxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(ethylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-B

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 643017-39-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-6-yl]propyl]-1-methyl-5-(4-methylbenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-B

PAGE 2-A

IT 643016-99-3P 643017-08-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of steroid-containing macrolide erythromycin analog glycosides for
treatment of inflammatory diseases)
RN 643016-99-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-[3-[(2R,3S,4R,5R,8R,10R,11R,12S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-6-yl]propyl]-5-methoxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 643017-08-7 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-[3-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(methylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-6-yl]propyl]-5-methoxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:322843 CAPLUS
DOCUMENT NUMBER: 136:402299
TITLE: Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane
AUTHOR(S): Bech, G. Ch.; Yard, B. A.; Schulte, J.; Oberacker, P.; Van Ackern, K.; Van der Woude, F. J.; Krinsky, M.; Kaszkin, M.; Yedgar, S.
CORPORATE SOURCE: Institute of Anaesthesiology, University of Mannheim, Mannheim, 68167, Germany
SOURCE: British Journal of Pharmacology (2002), 135(7), 1663-1674
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In acute respiratory distress syndrome (ARDS) induced by endotoxins, a high production of inflammatory mediators by microvascular lung endothelial cells (LMVEC) can be observed. Activation of cells by endotoxins may result in elevated secretion of phospholipase A2 (sPLA2) which is thought to contribute to tissue damage. The present study was undertaken to investigate the role of sPLA2 in chemokine production in human lung microvascular endothelial cells (LMVEC) stimulated with the endotoxins lipopolysaccharide (LPS) and lipoteichoic acid (LTA). In particular, we investigated the effects of sPLA2 inhibitors, specifically, the extracellular PLA2 inhibitors (ExPLIs), composed of N-derivatized phosphatidyl-ethanolamine linked to polymeric carriers, and LY311727, a specific inhibitor of non-pancreatic sPLA2. ExPLIs markedly inhibited LPS and LTA induced production and mRNA expression of the neutrophile attracting chemokines IL-8, Gro-α and ENA-78, as well as of the adhesion mols. ICAM-1 and E-selectin. Concomitantly, ExPLIs inhibited the LPS-induced activation of NF-κB by LPS but not its activation by TNF-α or IL-1. Endotoxin mediated chemokine production in LMVEC seems not to involve PLA2 activity, since LPS stimulation was not associated with activation of extracellular or secreted PLA2. It therefore seems that the inhibitory effect of the ExPLIs was not due to their PLA2 inhibiting capacity. This was supported by the finding that the LPS-induced chemokine production was not affected by the selective sPLA2 inhibitor LY311727. It is proposed that the ExPLIs may be considered a prototype of potent suppressors of specific endotoxin-induced inflammatory responses, with potential implications for the therapy of subsequent severe inflammation.
IT 164083-84-5, LY311727
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ExPLIs; inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to membrane)
RN 164083-84-5 CAPLUS

L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:537947 CAPLUS
DOCUMENT NUMBER: 133:236701
TITLE: Secretory and cytosolic phospholipase A2 regulate the long-term cytokine-induced eicosanoid production in human keratinocytes
AUTHOR(S): Sjoeren, Wenche; Brekke, Ole-Lars; Johansen, Berit
CORPORATE SOURCE: UNIGEN Center for Molecular Biology, Norwegian University of Science and Technology, NTNU, Trondheim, N-7489, Norway
SOURCE: Cytokine (2000), 12(8), 1189-1194
CODEN: CYTIE9; ISSN: 1043-4666
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The involvement of cytosolic phospholipase A2 (cPLA2) and secretory non-pancreatic PLA2 (sPLA2) in release of arachidonic acid (AA) preceding eicosanoid formation in the human keratinocyte cell line HaCaT was examined. Interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF), phorbol myristate acetate (PMA) and calcium ionophore A23187 increased the extracellular AA release, and stimulated eicosanoid synthesis as determined by RPLC anal. The main metabolites after stimulation with IL-1β, PMA or A23187 were PGE2, an unidentified PG and LTB4, while TNF stimulated HETE production. Both sPLA2and cPLA2messenge and enzyme activity were detected in unstimulated HaCaT cells. IL-1β, PMA and TNF increased both sPLA2 enzyme activity and expression, but did not lead to any increase in cPLA2 expression or activity. The selective cPLA2 inhibitors LY311727 and 12-epi-scalaradial, or the sPLA2 inhibitor arachidonyl trifluoro Me ketone (AACOCF3) reduced IL-1β-induced eicosanoid production in a concentration dependent manner. The results presented strongly suggest that both cPLA2 and sPLA2 contribute to the long-term generation of AA preceding eicosanoid production in differentiated, human keratinocytes. Inhibitors against sPLA2 as cPLA2 enzymes should be useful in treating inflammatory skin diseases, such as psoriasis. (c) 2000 Academic Press.
IT 164083-84-5, LY311727
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretory and cytosolic phospholipase A2 inhibitors for treatment of inflammatory skin diseases and psoriasis)
RN 164083-84-5 CAPLUS
CN Phosphonic acid, P-[3-[[3-[2-amino-2-oxoethyl]-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]propyl]- (CA INDEX NAME)

L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Phosphonic acid, P-[3-[[3-[2-amino-2-oxoethyl]-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]propyl]- (CA INDEX NAME)

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:508114 CAPLUS
DOCUMENT NUMBER: 125:108114
ORIGINAL REFERENCE NO.: 125:17379a,17342a
TITLE: Effect of MED 15 and tolmetin on the mouse immune system
AUTHOR(S): De Simone, Claudio; Baldinelli, L.; Cilli, A.; De Santis, S.; Sanzoglu, S.; Sosnia, M.
CORPORATE SOURCE: Policlin. Umberto, Univ., Rome "La Sapienza", Rome, Italy
SOURCE: International Journal of Immunotherapy (1996), 2(2), 155-61
CODEN: IJIMET; ISSN: 0255-9625
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

AB The influence of MED 15 (I) [104076-16-6] a recently synthesized nonsteroid anti-inflammatory drug and putative inhibitor of prostaglandin synthetase, on the mouse immune system was evaluated. The drug was compared with tolmetin [26171-23-3]. The results obtained support that MED 15 potentiates the in vitro primary antibody response, the [3H]thymidine and [3H]-leucine incorporation, and the interleukin 2 production, inhibits the splenocyte chemiluminescence, and has no effect on the primary in vivo immunization. Similar results, though less effective, were observed with tolmetin.
IT 87744-66-7
RL: BIOL (Biological study)
(immunity response to)
RN 87744-66-7 CAPLUS
CN Glycine, N-[2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]-, 2-methoxyphenyl ester (CA INDEX NAME)



```
=> D HIS

     (FILE 'HOME' ENTERED AT 12:46:53 ON 15 AUG 2009)

     FILE 'REGISTRY' ENTERED AT 12:47:13 ON 15 AUG 2009
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3             4 S L2
L4            76 S L2 FULL
L5            33 S L1
L6          1791 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 12:48:00 ON 15 AUG 2009
L7           377 S L6
L8            96 S L4
L9           451 S L7 OR L8
L10          167 S L9 AND INFLAMMATION
L11          179 S L9 AND INFLAMMATORY
L12          240 S L10 OR L11
L13            7 S L12 AND INTERLEUKIN

=> D IBIB ABS HITSTR L12 220-240
```

L12 ANSWER 220 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1978:69748 CAPLUS
DOCUMENT NUMBER: 88:99748
ORIGINAL REFERENCE NO.: 88:15115a,15118a
TITLE: Indomethacin esters acting as anti-inflammatory and immunosuppressive drugs
AUTHOR(S): Barcsewski, J.; Borja, J. M.; Sunkel, C.; Portoles, A.
CORPORATE SOURCE: Inst. Inmunol. Biol. Microbiana, Velazquez, Spain
SOURCE: International Journal of Clinical Pharmacology and Biopharmacy (1978), 16(5), 235-9
CODEN: IJPBDQ; ISSN: 0341-0226
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

AB Administration of indomethacin (I) [53-86-1] and 10 different I derivs. to mice depressed immune response to sheep red blood cells. Compds. with a lower toxicity than I and predominant immunosuppressive or antiinflammatory activity were obtained. According to the variations in the primary immune response and to their variable antiinflamatory actions, the structure-activity relationships are documented and some possible explanations, relative to their immunodepressive effect, are discussed.
IT 67379-02-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiinflammatory and immunosuppressive activity of)
RN 67379-02-7 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-cyclopentyl-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 220 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 221 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1978:69681 CAPLUS
DOCUMENT NUMBER: 88:84681
ORIGINAL REFERENCE NO.: 88:12875a,12876a
TITLE: Correlations of DNA, RNA and protein levels in duodenal mucosa with antiinflammatory potency and disposition to gut damage of non-steroidal agents. Comparative behavior of glucametacine, indomethacin, phenylbutazone and ibuprofen
AUTHOR(S): Parodi, E.; Menozzi, P.; Arania, M. C.
CORPORATE SOURCE: 2nd Inst. Med. Pharmacol., Univ. Rome, Rome, Italy
SOURCE: Arzneimittel-Forschung (1978), 28(5), 819-24
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

AB Glucametacine (I) [52443-21-7] was half as potent as indomethacin [53-86-1], twice as active as phenylbutazone [50-33-9] and 4 times more effective than ibuprofen [15687-27-1] in preventing cotton granuloma. Both indomethacin and phenylbutazone induced dose related gastrointestinal ulcerations and an increase of 51Cr-tagged erythrocytes in feces. The former drug displayed gut toxicity at antiinflammatory doses, the latter at doses approx. 4 times larger. I was still devoid of damaging effects at a dose 10 times larger than the minimal one capable of inhibiting granuloma growth. Ibuprofen also failed to induce ulcers at all doses examined; however, it displayed a trend toward gut bleeding when doses that increased blood corticosterone were given. Studies on duodenal mucosa showed that in rats on cotton granuloma, DNA, proteins and DNA:RNA ratio increase as compared to unimplanted rats. I and phenylbutazone reversed the increase of DNA and proteins, resp. Indomethacin decreased all forementioned constituents of duodenal mucosa while inducing hemorrhages and ulcers on gut. Furthermore, in naive rats, unlike I and phenylbutazone, indomethacin induced a decrease in protein content of duodenal mucosa. Differences in disposition of gut toxicity among I and other antiinflammatory drugs are discussed.
IT 52443-21-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of, nucleic acids and proteins of intestine in relation to)

L12 ANSWER 221 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 52443-21-7 CAPLUS
CN D-Glucose, 2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino]-2-deoxy- (CA INDEX NAME)
Absolute stereochemistry.



L12 ANSWER 222 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:567682 CAPLUS
DOCUMENT NUMBER: 87:167682
ORIGINAL REFERENCE NO.: 87:26491a,26494a
TITLE: The chemistry of etofenamate, a novel antiinflammatory
agent from the series of N-arylanthranilic acid derivatives
AUTHOR(S): Bolte, H. E.; Kreuzfeld, H.
CORPORATE SOURCE: Abt. Chem. Forsch., Troponwerke G.m.b.H. und Co. K.-G., Cologne, Fed. Rep. Ger.
SOURCE: Arzneimittel-Forschung (1977), 27(6), 1700-12
CODEN: ARZNAV; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB The title compound (I) was prepared conventionally in several ways (e.g., reaction of 2-(3-CF3C6H4NHC6H4CO2K with ClCH2CH2Cl) and tested as an inflammation inhibitor. Test data, and in some cases spectral data, for 47 analogs were also given.
IT 64152-93-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(antiinflammatory activity of)
RN 64152-93-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-[4-chlorobenzoyl]-5-methoxy-2-methyl-N-[2-[[3-[trifluoromethyl]phenyl]amino]benzoyl]- (CA INDEX NAME)

L12 ANSWER 222 OF 240 CAPLUS (Continued)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L12 ANSWER 223 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:177247 CAPLUS
DOCUMENT NUMBER: 85:177247
ORIGINAL REFERENCE NO.: 85:28329a,28322a
TITLE: Acyl-substituted pyrroles
INVENTOR(S): Carson, John R.
PATENT ASSIGNEE(S): McNeil Laboratories, Inc., USA
SOURCE: U.S., 28 pp. Division of U.S. 3,865,840.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3952012	A	19760420	US 1974-493965	19740617
FR 8113	M	19700803	FR 1968-8133	19680725
NL 6810664	A	19690128	NL 1968-10664	19680726
NL 162638	B	19800115		
NL 162638	C	19800616		
AT 296880	B	19710910	AT 1970-4663	19680726
AT 296886	B	19710910	AT 1970-4664	19680726
ZA 6805748	B	19751204	ZA 1968-5805	19680726
US 3752826	A	19730814	US 1970-5958	19700126
BE 742040	A4	19700726	BE 1971-98986	19710126
US 3865840	A	19750211	US 1973-338463	19730216
JP 50039463	B	19751218	JP 1974-26714	19740307
DK 7500133	A	19750804	DK 1975-133	19750117
DK 7500134	A	19750804	DK 1975-134	19750117
DK 133773	B	19770418		
IN 142787	A2	19761030	IN 1975-CA491	19750313
IN 140718	A1	19751211	IN 1975-CA1126	19750605
PRIORITY APPLN. INFO.:			US 1967-654674	A2 19670726
			US 1968-741348	A2 19680701
			US 1970-5958	A3 19700126
			US 1973-338463	A3 19730216
			BE 1968-718594	A 19680725
			DK 1968-3611	A 19680726
			IN 1970-129759	A1 19701228

OTHER SOURCE(S): MARPAT 85:177247
GI



I

L12 ANSWER 223 OF 240 CAPLUS (Continued)

AB About 100 pyrroles I (R = CH2CN, CH2CO2R, CH2CONR2, CH2CO2Et, CHMeCO2R, CHEtCH2CO2R, etc.; R1 = Me, PhCH2, Et, H; R2 = Ph, p-ClC6H4, 2-thienyl, o-MeC6H4, etc., R3 = H, Me) were prepared by arylation of pyrroles. Thus, N-methyl-2-pyrroleacetonitrile was acylated with PhCOCl and AlCl3 to give I (R = CH2CN, R1 = Me, R2 = Ph, R3 = H) which was hydrolyzed to give I (R = CH2CO2H). At 25 mg/kg I (R = CH2CO2H, R1 = Me, R2 = p-ClC6H4, R3 = H) inhibited kaolin-induced rat paw edema by 47%.
IT 26235-67-6P 26235-68-7P 33369-24-3P 33369-25-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)
RN 26235-67-6 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-1-methyl- (CA INDEX NAME)



RN 26235-68-7 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-N-ethyl-1-methyl- (CA INDEX NAME)



RN 33369-24-3 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-N-hydroxy-1-methyl- (CA INDEX
NAME)



L12 ANSWER 223 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 37369-25-4 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-[(4-chlorobenzoyl)-N-[2-(diethylamino)ethyl]-1-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

L12 ANSWER 224 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:446324 CAPLUS
DOCUMENT NUMBER: 85:46324
ORIGINAL REFERENCE NO.: 85:7539a,7522a
TITLE: Synthesis of some 1-chloropyridinoyl-2-methyl-5-methoxy-3-indolylacetic acids and pyridylmethylamides of 1-(4-chloronicotinoyl)-2-methyl-5-methoxy-3-indolylacetic acid
AUTHOR(S): Winiecki, Stanislaw; Lompke, Tadeusz
CORPORATE SOURCE: Inst. Drog Sci., Sch. Med., Warsaw, Pol.
SOURCE: Roczniki Chemii (1976), 50(2), 315-21
CODEN: ROCHAV; ISSN: 0035-7677
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 85:46324
GI



AB The potential antiinflammatory agents I (R = 2-chloro-7-, 6-chloro-7-, 4-chloro-2-pyridyl) were prepared by cyclization of MeOC6H3CHRCO2H with p-MeOC6H4N(COR)NHCHO, obtained by condensation of p-MeOC6H4NHNHCHO with the appropriate chloropyridylnicotinoyl chloride.
IT 59823-63-1P 59823-64-2P 59823-65-3P
RL: SYN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59823-63-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(6-chloro-3-pyridinyl)carbonyl]-5-methoxy-2-methyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)



L12 ANSWER 224 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 59823-64-2 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(6-chloro-3-pyridinyl)carbonyl]-5-methoxy-2-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 59823-65-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(6-chloro-3-pyridinyl)carbonyl]-5-methoxy-2-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



L12 ANSWER 225 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:43747 CAPLUS
DOCUMENT NUMBER: 84:43747
ORIGINAL REFERENCE NO.: 84:7169a,7172a
TITLE: Synthesis and antiphlogistic properties of some indolylacetohydroxamic acids
AUTHOR(S): De Martiis, F.; Franzone, J. S.; Tanzetto, I.
CORPORATE SOURCE: Lab. Ric., Ist. Biol. Chemioter. "ABC", Turin, Italy
SOURCE: Bollettino Chimico Farmaceutico (1975), 114(6), 309-18
CODEN: BCFAAI; ISSN: 0006-6648
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB Indoleacetates I (R = COCSH4Cl-4, R1 = Cl, NHOR, NH2, morpholino, NMe2, OMe, OEt; R = H, R1 = NHOR; R = CH2Ph, allyl, R1 = OMe, NHOH; R = CH2CO2Et, CH2CONHOR, R1 = OMe, OCMe3) were prepared from indomethacin. At 10 mg/kg orally I gave 13-62% inhibition of carrageenin edema in rats and at 5 mg/kg orally caused 12-48% increase in pain threshold in rats.
IT 6264-33-1P 34024-38-9P 34024-39-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and antiinflammatory activity of)
RN 6264-33-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 34024-38-9 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(2-propen-1-yl)- (CA INDEX NAME)

L12 ANSWER 225 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 34024-39-0 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(phenylmethyl)- (CA INDEX NAME)



IT 27035-30-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, hydrolysis, and pharmacological activity of)
RN 27035-30-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 225 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L12 ANSWER 226 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:17731 CAPLUS
DOCUMENT NUMBER: 84:17731
ORIGINAL REFERENCE NO.: 84:2951a,2954a
TITLE: Indolylacetyl amino acid derivatives
INVENTOR(S): Biere, Helmut; Ahrens, Hanns; Rufer, Clemens; Schroeder, Eberhard; Koch, Henning
PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2413125	A1	19751009	DE 1974-2413125		19740315
DE 2413125	C2	19830630			
DK 7500855	A	19750916	DK 1975-855		19750303
US 3962471	A	19760608	US 1975-557515		19750312
SE 7502833	A	19750916	SE 1975-2833		19750313
DD 118629	A5	19760312	DD 1975-184745		19750313
AU 7579039	A	19760916	AU 1975-79039		19750313
BE 826711	A1	19750915	BE 1975-154355		19750314
NL 7503110	A	19750917	NL 1975-3110		19750314
JP 50129548	A	19751013	JP 1975-31003		19750314
HU 170750	B	19770828	HU 1975-SC513		19750314
FR 2263770	A1	19751010	FR 1975-8200		19750317
PRIORITY APPLN. INFO.:			DE 1974-2413125	A	19740315

GI For diagram(s), see printed CA Issue.
AB Indolylacetylamino acids I [R = H, R1 = H, R2 = OH (L), R1 = Me, R2 = OH (DL); R1 = H, R2 = OMe (DL); R1 = H, R2 = NHMe (DL); R = Me, R1 = H, R2 = OH (DL)] useful as antiinflammatory agents, were prepared in 50-65% yields by treating the indolylacetic acid with ClCO2CH2CHMe2, then with RCH(OR1)CH(NH2)COR2 at -10 to -15°. I (R = R1 = H, R2 = OH) gave 48 and 35% inhibition of rat paw edema after 16 and 40 hr, resp., at 22.3 + 10-6 mole/kg, whereas indometacine II gave 47 and 46%, resp., but II gave more severe stomach lesions than I(R = R2 = H, R2 = OH).
IT 57645-05-3P 57645-06-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory activity of)
RN 57645-05-3 CAPLUS
CN L-Serine, N-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 226 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 57645-06-4 CAPLUS
CN Serine, N-[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]-O-methyl- (9CI) (CA INDEX NAME)



IT 57645-07-5P 57645-08-6P 57645-09-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57645-07-5 CAPLUS
CN Serine, N-[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 226 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 57645-08-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-[4-chlorobenzoyl)-N-[1-(hydroxymethyl)-2-[methylamino]-2-oxoethyl]-5-methoxy-2-methyl- (CA INDEX NAME)



RN 57645-09-7 CAPLUS
CN Threonine, N-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 226 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L12 ANSWER 227 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:589394 CAPLUS
DOCUMENT NUMBER: 83:189394
ORIGINAL REFERENCE NO.: 83:29549a,29552a
TITLE: Pharmacotoxicological evaluation of a new neurotroidal antiinflammatory agent, indoxamic acid
AUTHOR(S): De Martiis, F.; Curaio, N.; Franzone, J. S.; Zanietto, T.
CORPORATE SOURCE: Lab. Ric., Ist. Biol. Chemioter. "ABC", Turin, Italy
SOURCE: Bollettino Chimico Farmaceutico (1975), 114(6), 319-33
CODEN: BCFAAI; ISSN: 0006-6648
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB The antiinflammatory, antipyretic, and analgesic activities of indoxamic acid [I] [27035-30-9] were comparable to those of indomethacin [II] [53-86-1], as determined by a number of standard pharmacol. tests on rats and mice. However, I was less toxic than II, and also less ulcerogenic to the gastrointestinal tract. As a result, the therapeutic index of I was 2-4-fold more favorable than that of II.
IT 27035-30-9
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (pharmacol. and toxicity of)
RN 27035-30-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 228 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:140106 CAPLUS
DOCUMENT NUMBER: 82:140106
ORIGINAL REFERENCE NO.: 82:22387a,22390a
TITLE: 3-Indolyl-fatty acid amides and salts thereof
INVENTOR(S): Okamoto, Tadashi; Kobayashi, Teruyoshi; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JKXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49020591	B	19740525	JP 1969-45689	19690609
PRIORITY APPLN. INFO.:			JP 1969-45689	19690609

GI For diagram(s), see printed CA Issue.
AB 1-(3,4-Methylenedioxybenzoyl)indole-3-acetamide [I, R = NH2 (II), morpholino, NHCH2CH2OH, NH2], useful as analgesics, antipyretics, and antiinflammatory agents, were prepared by treating phenylhydrazine III with MeCOCHCHCO2R. E.g., III was treated with MeCOCHCHCO2NHMe2 in HOCHMe2 at 85° for 4 hr to give II.
IT 26487-29-6P 55173-50-7P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 26487-29-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-(3,3-benzodioxol-5-ylacrbonyl)-N-(2-hydroxyethyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 55173-50-7 CAPLUS
CN 1H-Indole-3-acetamide, 1-(3,3-benzodioxol-5-ylacrbonyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 228 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L12 ANSWER 229 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:125273 CAPLUS
DOCUMENT NUMBER: 82:125273
ORIGINAL REFERENCE NO.: 82:20013a,20014a
TITLE: N1-Acylated phenylhydrazone compounds
INVENTOR(S): Yamamoto, Hisao; Nakao, Masaru
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: U.S., 32 pp. Division of U. S. 3,629,284 (CA 76:113066g).
CODEN: USXAAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3770752	A	19731106	US 1970-64042	19700729
DE 1793670	A	19720525	DE 1967-1793670	19660415
DK 123977	B	19720828	DK 1968-1568	19680408
US 3629284	A	19711221	US 1969-838037	19690623
NO 127863	B	19730827	NO 1970-1613	19700427
FI 53307	C	19780410	FI 1971-672	19710308
PRIORITY APPLN. INFO.:			JP 1966-5754	A 19660131
			JP 1965-24928	A 19650426
			JP 1965-75793	A 19651208
			US 1969-838037	19690623
			US 1966-541967	19660412
			JP 1965-23078	A 19650419
			JP 1965-24929	A 19650426
			JP 1965-24930	A 19650426
			JP 1965-73856	A 19651130
			JP 1965-73857	A 19651130
			JP 1965-75430	A 19651207
			JP 1965-75792	A 19651208
			JP 1966-81794	A 19651229
			JP 1966-81795	A 19651229
			JP 1966-81796	A 19651229
			JP 1966-7187	A 19660120

L12 ANSWER 229 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

		JP 1966-7276	A 19660207
		JP 1966-7277	A 19660207
		NO 1966-162587	A 19660414
		FI 1966-995	A 19660418

GI For diagram(s), see printed CA Issue.

AB The indoles I [n = 1,3; R = H, Et; R1 = Ph, p-ClC6, p-F3CC6H4, 3-pyridyl, 4-pyridyl, et;ry R2 = H, MeO) were prepared from arylhydrazines. Thus, p-MeOC6H4NHN:CMe2 was treated with p-ClC6H4COCl and the product treated with HCl to give p-MeO-C6H4N(HCl)COC6H4Cl-p.HCl, which was cyclized with MeCO(CH2)4COCl8 to give I (n = 3, R = H, R1 = p-ClC6H4, R2 = MeO). The antiinflammatory ED50 of I (n = 1, R = H, R1 = 3-pyridyl, R2 = MeO) is 105 mg/kg. I are antipyretic and analgesic.

IT 6264-33-1P
RL: SPH (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 6264-33-1 CAPLUS

CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



L12 ANSWER 230 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:125272 CAPLUS
DOCUMENT NUMBER: 82:125272
ORIGINAL REFERENCE NO.: 82:20014a,20014a
TITLE: d-Indolyl aliphatic acid compounds
INVENTOR(S): Yamamoto, Hisao; Nakao, Masaru
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: U.S., 13 pp. Division of U.S. 3,629,284 (CA 76:113060g).
CODEN: USXAAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3922275	A	19760702	US 1970-64841	19700729
DE 1793670	A	19720525	DE 1967-1793670	19660415
DE 1795671	A	19730412	DE 1967-1795671	19660415
DK 123977	B	19720828	DK 1968-1568	19680408
US 3629284	A	19711221	US 1969-838037	19690623
NO 127863	B	19730827	NO 1970-1613	19700427
FI 53307	C	19780410	FI 1971-672	19710308
FI 48834	B	19740930	FI 1972-459	19720221
PRIORITY APPLN. INFO.:			JP 1965-24928	A 19650426
			JP 1965-75793	A 19651208
			JP 1966-5754	A 19660131
			JP 1966-7276	A 19660207
			JP 1966-7277	A 19660207
			US 1966-541967	A1 19660412
			US 1969-838037	A3 19690623
			JP 1965-23078	A 19650419
			JP 1965-24929	A 19650426
			JP 1965-24930	A 19650426
			JP 1965-73856	A 19651130
			JP 1965-73857	A 19651130
			JP 1965-75430	A 19651207
			JP 1965-75792	A 19651208
			JP 1966-81794	A 19651229
			JP 1966-81795	A 19651229
			JP 1966-81796	A 19651229

L12 ANSWER 230 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

JP 1966-3187	A	19660120
NO 1966-162587	A	19660414
FI 1966-995	A	19660418

GI For diagram(s), see printed CA Issue.
AB Indomethacin analogs I (R = 3-pyridyl, 4-pyridyl, 2-thienyl, 2-furyl, 5-chloro-2-thienyl, Ph, 2-naphthyl; p-R2C6H4; R2 = Cl, Me, OMe, CF3, SMe, Br, F; R1 = H, OMe, Me, SMe, Cl, F, NO2, OEt), some of their esters and some related indolealkanoic acids were prepared Thus, I (R = 3-pyridyl,
R1
= OMe) (II) was obtained by acylating p-MeOC6H4NHN:CHMe with nicotinoyl chloride, treating with HCl(g) to give N-nicotinoyl-N-(p-methoxyphenyl)hydrazine, which (4.9 g) was condensed with 17.6 g levulinic acid to give 5.8 g II. On the carrageenin edema test in rats II had an oral ED50 of 80 mg/kg and a therapeutic ratio of >18.8.
IT 6264-33-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 6264-33-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L12 ANSWER 231 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1974:449563 CAPLUS
DOCUMENT NUMBER: 81:49563
ORIGINAL REFERENCE NO.: 81:7911a,7914a
TITLE: N'-Heteroacylated phenylhydrazines
INVENTOR(S): Yamamoto, Hisao; Nakao, Masaru
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: U.S., 12 pp. Division of U.S. 3,629,284 (CA 76;113060g).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 3810906	A	19740514	US 1970-64843		19700729
US 3629284	A	19711221	US 1969-838037		19690623
PRIORITY APPLN. INFO.:			US 1966-541967	A1	19660412
			US 1969-838037	A3	19690623
			JP 1965-23078	A	19650419
			JP 1965-24928	A	19650426
			JP 1965-24929	A	19650426
			JP 1965-24930	A	19650426
			JP 1965-73856	A	19651130
			JP 1965-73857	A	19651130
			JP 1965-75430	A	19651207
			JP 1965-75792	A	19651208
			JP 1965-75793	A	19651208
			JP 1966-81794	A	19651229
			JP 1966-81795	A	19651229
			JP 1966-81796	A	19651229
			JP 1966-3187	A	19660120
			JP 1966-5754	A	19660131
			JP 1966-7276	A	19660207
			JP 1966-7277	A	19660207

L12 ANSWER 231 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
GI For diagram(s), see printed CA Issue.
AB RCON(NH2)C6H4R1 (I, R = p-ClC6H4, p-MeC6H4, Ph, p-MeOC6H4, p-F3CC6H4, p-BrC6H4, p-FC6H4, 3-pyridyl, 4-pyridyl, 2-thienyl, 5-chloro-2-thienyl, 2-furyl, p-MeSC6H4, 2-naphthyl; R1 = H, p-Cl, p-Me, p-MeO, p-F, m-Me, p-MeS, p-NO2, p-EtO) (25 compds.) were prepared by acylating
MeCH:-NNHC6H4R1
and treating the MeCH:NN(COR)C6H4R1 with HCl(g). I were cyclized with R2COZCO2R3 (R2 = H, Me; Z = CH2, CHMe, (CH2)2, (CH2)3; R3 = H, Me, Et, CMe3, CH2Ph) to give the indoles II (42 compds.). II (R = 3-pyridyl, 4-pyridyl, R1 = 5-MeO, R2 = Me, R3 = H, Z = CH2) had oral
antiinflammatory
ED50 in the rat paw edema test of 80 and 105 mg/kg, resp., and
therapeutic
ratios >18.8 and >14.3, resp.
IT 6264-33-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 6264-33-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



L12 ANSWER 232 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1974:83529 CAPLUS
DOCUMENT NUMBER: 80:83529
ORIGINAL REFERENCE NO.: 80:13453a,13456a
TITLE: Antiinflammatory d-(+)-glucosamide of 1-(4-chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid
INVENTOR(S): Antoniu, Demetrio; Ganzina, Fabrizio; Magi, Mario; Serino, Enrico; Paroli, Eugenio; Samueli, Fabio
PATENT ASSIGNEE(S): SIR Laboratori Chimico Biologici S.p.A.
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2223051	A1	19731213	DE 1972-2223051		19720512
DE 2223051	C2	19830203			
AU 7355064	A	19741107	AU 1973-55064		19730501
GB 1383465	A	19750212	GB 1973-21278		19730504
ZA 7303106	A	19740327	ZA 1973-3106		19730508
CH 606072	A5	19781013	CH 1973-6511		19730508
NL 7306501	A	19731113	NL 1973-6501		19730509
NL 179136	B	19860217			
NL 179136	C	19860716			
FR 2184033	A1	19731221	FR 1973-16793		19730509
JP 49066814	A	19740628	JP 1973-50816		19730509
JP 61003800	B	19860204			
CA 980767	A1	19751230	CA 1973-170835		19730509
PRIORITY APPLN. INFO.:			IT 1972-24118	A	19720509
			IT 1973-20391		19730214

AB The glucosamide (I) of the indoleacetic acid was prepared by amidation of the acid chloride with glucosamine in inert solvents in the presence of NaOH. I had antiphlogistic activity at low toxicity.
IT 52443-21-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52443-21-7 CAPLUS
CN D-Glucose, 2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 232 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L12 ANSWER 233 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1974:3377 CAPLUS
DOCUMENT NUMBER: 80:3377
ORIGINAL REFERENCE NO.: 80:587a,590a
TITLE: Antiinflammatory 5-acylpyrroles
INVENTOR(S): Carson, John R.
PATENT ASSIGNEE(S): McNeil Laboratories, Inc.
SOURCE: Ger. Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2302671	A1	19730726	DE 1973-2302671		19730119
US 3803169	A	19740409	US 1972-219861		19720121
US 3803171	A	19740409	US 1972-219864		19720121
AU 7350905	A	19740711	AU 1973-50905		19730109
BE 794160	A1	19730717	BE 1973-126560		19730117
FR 2183658	A1	19731221	FR 1973-1764		19730118
AT 7300473	A	19750215	AT 1973-473		19730119
AT 326115	B	19751125			
GB 1390866	A	19750416	GB 1973-2854		19730119
CA 996939	A1	19760914	CA 1973-161656		19730119
CH 587815	A5	19770513	CH 1973-824		19730119
JP 48080556	A	19731029	JP 1973-9400		19730122
PRIORITY APPLN. INFO.:			US 1972-219861	A	19720121
			US 1972-219864	A	19720121

GI For diagram(s), see printed CA Issue.
AB Ten pyrroles (I; R = H, Me, or Et; R1 = H or Me; R2 = CN, CONH2, CO2H, or CO2Et; R3 = PhCH2CO or cyclohexylcarbonyl) were prepared by reaction of I (R3 = H) with R3Cl in the presence of AlCl3 or SnCl4 and optionally subsequent alkylation. Hydrolysis of I (R2 = CN) gave I [R2 = CONH2 or CO2H (II)]. II were also prepared by saponification of I (R2 = CO2Et). II had antiinflammatory activity in rats.
IT 50551-23-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50551-23-0 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(cyclohexylcarbonyl)-1-methyl- (CA INDEX NAME)



L12 ANSWER 233 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1973:442278 CAPLUS
DOCUMENT NUMBER: 79:42278
ORIGINAL REFERENCE NO.: 79:6873a,6876a
TITLE: Substituted anilides of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
AUTHOR(S): Linari, G.; Spano, R.
CORPORATE SOURCE: Ist. Farm. Biol., Stroder s.v.l., Florence, Italy
SOURCE: Arzneimittel-Forschung (1973), 23(1), 89-91
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Twenty-five title compds. (I, Rn = H, 2-, 3-, or 4-Cl or -Br or -NO2, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-Cl2, 2,4- or 2,5-Br2, 4,2-, 4,3-, or 2,4-ClNO2, 2,3-Me2, 2,3-, 2,4-, or 2,5-MeCl) were prepared by reaction of indomethacin (II) with H2NC6H5-nRn and PCl3. The antiinflammation and antipyretic effects of I were not higher than that of II. With respect to the analgesic activity, only I (Rn = 2,4-, 2,5-, 2,6- or 3,5-Cl2, 2,4- or 2,5-Br2, and 3-NO2) were more effective than II.
IT 41736-43-0P 41736-44-1P 41752-62-9P
41752-63-0P 41752-64-1P 41752-65-2P
41752-66-3P 41752-67-4P 41752-68-5P
41752-69-6P 41752-70-9P 41752-71-0P
41752-72-1P 41752-73-2P 41752-74-3P
41752-75-4P 41752-76-5P 41752-77-6P
41752-78-7P 41752-79-8P 41752-80-1P
41752-81-2P 41752-82-3P 41752-83-4P
41752-84-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41736-43-0 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,6-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41736-44-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(3,5-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-62-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(3-chlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-63-0 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(4-chlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-64-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,3-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-65-2 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,4-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

RN 41752-66-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,5-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

RN 41752-67-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(3,4-dichlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-68-5 CAPLUS
CN 1H-Indole-3-acetamide, N-(2-bromophenyl)-1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-69-6 CAPLUS
CN 1H-Indole-3-acetamide, N-(3-bromophenyl)-1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 41752-70-9 CAPLUS
CN 1H-Indole-3-acetamide, N-(4-bromophenyl)-1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-71-0 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,4-dibromophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-72-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,3-dibromophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-75-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-(4-nitrophenyl)- (CA INDEX NAME)



RN 41752-76-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(4-chloro-2-nitrophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-73-2 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-(2-nitrophenyl)- (CA INDEX NAME)



RN 41752-74-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-(3-nitrophenyl)- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-77-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(4-chloro-2-nitrophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-78-7 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2-chloro-4-nitrophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-79-8 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2,3-dimethylphenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-89-0 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(3-chloro-2-methylphenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-93-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-phenyl- (CA INDEX NAME)



RN 41752-84-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(3-chlorophenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 41752-81-2 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(4-chloro-2-methylphenyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41752-82-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(5-chloro-2-methylphenyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 234 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L12 ANSWER 235 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1973:94254 CAPLUS
DOCUMENT NUMBER: 78:94254
ORIGINAL REFERENCE NO.: 78:13445a,13446a
TITLE: N-(1-Acyl-2-methyl-5-methoxyindole-3-acetyl)methionines
INVENTOR(S): Okamoto, Tadaaki; Kobayashi, Tsuyoshi; Sato, Hiromi; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 2 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47044221	B4	19721108	JP 1969-90956	19691112

GI For diagram(s), see printed CA Issue.
AB The title compds. [I] are anti-inflammatory agents with less side effects. Thus, 1-cinnamoyl-2-methyl-5-methoxyindole-3-acetic acid was activated with C1OCEt and Et3N in THF and added to L-methionine and KOH in H2O to give I (R = PhCH:CH). Also prepared were I [R = p-ClC6H4 and 3,4-(methylenedioxy)phenyl].
IT 39779-12-9 39779-13-0 39779-14-1
RL: PAC (Reactant); RACT (Reactant or reagent)
(antiinflammatory)
RN 39779-12-9 CAPLUS
CN L-Methionine, N-[5-methoxy-2-methyl-1-[1-oxo-3-phenyl-2-propenyl]-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 39779-13-0 CAPLUS
CN L-Methionine, N-[[5-[4-chlorobenzoyl]-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 235 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 39779-14-1 CAPLUS
CN L-Methionine, N-[[1-[1,3-benzodioxol-5-ylcarbonyl]-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 236 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:513040 CAPLUS
DOCUMENT NUMBER: 74:113040
ORIGINAL REFERENCE NO.: 74:19259a,19256a
TITLE: Antiinflammatory N-acylindole-3-aliphatic acid derivatives
INVENTOR(S): Yamamoto, Hisao; Nakao, Nakao, Masaru
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3629284	A	19711221	US 1969-838037	19690623
JP 49045386	B	19741204	JP 1965-24929	19650426
JP 49045387	B	19741204	JP 1965-24930	19650426
DE 1793698	A	19720525	DE 1967-1793698	19660415
DE 1795671	A	19730412	DE 1967-1795671	19660415
AT 277211	B	19693210	AT 1967-6440	19660418
CH 517977	A	19711231	CH 1966-517977	19660418
CH 517978	A	19711231	CH 1966-517978	19660418
BE 743979	A	19701139	BE 1969-17388	19690418
CH 152995	B2	19740222	CH 1972-1101	19660418
BR 6786194	D0	19731206	BR 1967-186194	19670116
DK 123977	B	19720828	DK 1968-1568	19680408
DK 127839	B	19731210	DK 1969-1569	19680408
NO 127863	B	19730827	NO 1970-1613	19700427
US 3770782	A	19731106	US 1970-64842	19700729
US 3810906	A	19740514	US 1970-64843	19700729
US 3822375	A	19740702	US 1970-64841	19700729
FI 53307	C	19780410	FI 1971-672	19710308
FI 68834	B	19740930	US 1971-659	19710211
PRIORITY APPLN. INFO.:			JP 1965-23078 A	19650419
			JP 1965-24928 A	19650426
			JP 1965-24929 A	19650426
			JP 1965-24930 A	19650426
			JP 1965-77856 A	19651130
			JP 1965-77857 A	19651130
			JP 1965-75430 A	19651207
			JP 1965-75792 A	19651208
			JP 1965-75793 A	19651208
			JP 1966-81794 A	19651229
			JP 1966-81795 A	19651229
			JP 1966-81796 A	19651229

L12 ANSWER 236 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

		JP 1966-7187 A	19660210
		JP 1966-5754 A	19660131
		JP 1966-7276 A	19660207
		JP 1966-7277 A	19660207
		US 1966-541967	19660412
		NO 1966-162587 A	19660414
		FI 1966-995 A	19660418
		US 1969-838037	19690623

GI For diagram(s), see printed CA Issue.
AB The hydrazine (I, R = nicotinoyl, R1 = MeO) (II) was treated with As(OCH2CO2H)3 to give the indoleacetic acid (III, n = 1, R = nicotinoyl, R1 = MeO, R2 = R3 = H) (IV). About 90 similar III (R = nicotinoyl, 2-thenoyl, 2-furoyl, isonicotinoyl, p-ClC6H4CO, p-MeOC6H4CO, Br, p-MeC6H4CO, p-MeSC6H4CO, β-naphthoyl, p-EtC6H4CO, p-FC6H4CO; R1 = H, MeO, Me, Cl, F, EtO; R2 = H, Me; R3 = H, tert-Bu, PhCH2, Me, Et; n = 1, 2, 3) were prepared V (R = CH(CO2Et)2, CH2CONH2) were similarly prepared
IT was prepared by treatment of p-MeOC6H4-NHNH2•HCl with nicotinoyl chloride and treatment of the product with HCl. Several similar I (R1 = Me, MeO, Cl, R = nicotinoyl, 2-thenoyl, 2-furoyl, p-MeC6H4CO, p-ClC6H4CO) were prepared The ED50 of IV was 50 mg/kg for carrageenan-induced edema in rat paws. The LD50/ED50 was >10.0 for IV (Indomethacin was <6.5).
IT 6264-33-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 6264-33-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

L12 ANSWER 236 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(4 CITINGS)

L12 ANSWER 237 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1972:72402 CAPLUS
DOCUMENT NUMBER: 76:72402
ORIGINAL REFERENCE NO.: 76:11658h,11657a
TITLE: Antiinflammatory, antipyretic, and analgesic 2-methyl-5-methoxy-3-indoleacetohydroxamic acids
INVENTOR(S): De Martiis, Franco; Arrigoni-Martelli, Edoardo; Tamletto, Teresio
PATENT ASSIGNEE(S): Instituto Biologico Chemioterapico "ABC" S.p.A.
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3624127	A	19711130	US 1969-822730	19690506
NL 6910204	A	19691125	NL 1969-10204	19690719
			IT 1968-51749	A 19690521

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.
AB 2-Methyl-5-methoxy-3-indoleacetohydroxamic acids (I, R = allyl, benzyl, p-chlorobenzoyl, and H) were prepared and showed antiinflammatory, antipyretic, analgesic effects in rats. In an example, I (R = allyl) was prepared by treatment of the corresponding Me indoleacetate (II) with NH2OH·HCl in alc. II was prepared by treatment of Me 2-methyl-5-methoxy-3-indoleacetate with NaH and ClCH2CH:CH2 in DMF.
IT 6264-33-1P 27035-30-9P 34024-38-9P
34024-39-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 6264-33-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (CA INDEX NAME)



L12 ANSWER 237 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 27035-30-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl- (CA INDEX NAME)



RN 34024-38-9 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(2-propen-1-yl)- (CA INDEX NAME)



RN 34024-39-0 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L12 ANSWER 238 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:151668 CAPLUS
DOCUMENT NUMBER: 75:151668
ORIGINAL REFERENCE NO.: 75:23921a,23924a
TITLE: Pharmaceutical 2-methyl-5-methoxy-3-indolylacetohydroxamin acid derivatives
INVENTOR(S): DeMartiis, Franco; Arrigoni-Martelli, Edoardo; Tamletto, Teresio
PATENT ASSIGNEE(S): Istituto Biologico Chemioterapico ABC S.p.A.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2008332	A	19710902	DE 1970-2008332	19700223
DE 2008332	B2	19790809		
DE 2008332	C3	19800522		

PRIORITY APPLN. INFO.: DE 1970-2008332 19700223

GI For diagram(s), see printed CA Issue.
AB Indolylacetohydroxamic acids (I) [where R=NHOH, R1=CH2CH:CH2, PhCH2, p-ClC6H4CO, H; with antiphlogistic, antipyretic and analgesic effects and oral LD50 70-107 mg/kg in rats were prepared by reaction of the corresponding indolylacetic esters or acid chlorides with NH2OH. Thus, a mixture of 0.9 g I (R=OMe, R1=CH2CH:CH2) (II) in 4 ml MeOH and 14 ml 1/150 M NH2OH solution in MeOH was refluxed 30 min, MeOH distilled, and the pH adjusted to 6-6.5 with 2N HCl to give 0.55 g 1-allyl-2-methyl-5-methoxy-3-indolylacetohydroxamic acid. II was prepared by treatment of I (R=OMe, R1=H) with NaH/DMF, addition of ClCH2CH:CH2 in DMF, and 48 hr cooling of the mixture
IT 27035-30-9 34024-38-9 34024-39-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(analgesics and antiphlogistics)
RN 27035-30-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 238 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 34624-30-9 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(2-propen-1-yl)- (CA INDEX NAME)



RN 34624-39-0 CAPLUS
CN 1H-Indole-3-acetamide, N-hydroxy-5-methoxy-2-methyl-1-(phenylmethyl)- (CA INDEX NAME)



L12 ANSWER 239 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:469476 CAPLUS
DOCUMENT NUMBER: 75:95476
ORIGINAL REFERENCE NO.: 75:15561a,15564a
TITLE: Antiinflammatory 5-aroylpyrroles
INVENTOR(S): Carson, John F.
PATENT ASSIGNEE(S): Mobil Laboratories Inc.
SOURCE: Ger. Offen., 39 pp. Addn. to Ger. Offen. 1,770,984.
CODEN: GWXXEX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2102746	A	19710812	DE 1971-2102746	19710111
US 3752826	A	19730814	US 1970-5958	19700124
CH 547074	A	19740329	CH 1971-1015	19710122
GB 1347954	A5	19750330	GB 1973-6479	19710122
FR 2091455	A5	19711203	FR 1971-2743	19710125
FR 2091455	A2	19711203		
ZA 7100479	A	19720927	ZA 1971-479	19710125
AT 308735	B	19730725	AT 1972-7095	19710125
AT 313269	B	19740211	AT 1971-592	19710125
AT 313270	B	19740211	AT 1972-7096	19710125
AT 313271	B	19740211	AT 1972-7097	19710125
IL 36055	A	19740516	IL 1971-36055	19710125
SE 389670	B	19761115	SE 1971-839	19710125
BE 762060	A4	19710726	BE 1971-98956	19710126
NL 7101016	A	19710728	NL 1971-1016	19710126
JP 56009426	B	19810190	JP 1971-2589	19710126
GB 1327908	A	19730822	GB 1971-20090	19710419
IN 140718	A1	19761211	IN 1971-CA1126	19710605
JP 55023401	A	19800908	JP 1978-7119	19780125
JP 58002935	B	19830119		
JP 55023402	A	19800908	JP 1978-7119	19780125
JP 58002936	B	19830119		
JP 55162767	A	19801218	JP 1980-76933	19800605
JP 57045428	B	19820928		
JP 55162766	A	19801218	JP 1980-76934	19800605
JP 59001711	B	19840113		
PRIORITY APPLN. INFO.:			US 1970-5958	A 19700124
			US 1967-656974	A2 19670726
			US 1968-741748	A2 19680701
			BE 1968-718594	A 19680725
			IN 1970-129759	A1 19701228

GI For diagram(s), see printed CA Issue.
AB The antiinflammatory title compds. [I, Ar = 2-thienyl, 5-methyl-2-thienyl,

L12 ANSWER 239 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
or substituted phenyl; R = H, Me, Et, or CH2Ph; R1 = CH2CO2R, CH2CO2Et, CH2Cl, CO2H2, CH(Me)CO2R, CONHCH2CH2NEt2, CH2CH2CO2R, or CH2CONHOH; R2 = R, CO2R, or CO2Et; R3 = H, Me, or Et] were tested and (or) mostly prepd. by acylation of the corresponding pyrroles. Thus, refluxing 5-methyl-2-thienoyl chloride and [1-methylpyrrol-2-yl]acetonitrile in the presence of AlCl3 in ClCH2CH2Cl gave I [Ar = 5-methyl-2-thienyl, R = Me, R1 = CH2CN, R2 = R3 = H] (II). Hydrolysis of II with N NaOH in EtOH gave I [Ar = 5-methyl-2-thienyl, R = Me, R1 = CO2H, R2 = R3 = H]. About 70 compds. were prepd. and (or) tested.
IT 26235-67-6P 26235-68-7P 33369-24-3P
33369-25-4P 33369-51-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26235-67-6 CAPLUS
CN 1H-Pyrrole-1-acetamide, 5-(4-chlorobenzoyl)-1-methyl- (CA INDEX NAME)



RN 26235-68-7 CAPLUS
CN 1H-Pyrrole-1-acetamide, 5-(4-chlorobenzoyl)-N-ethyl-1-methyl- (CA INDEX NAME)



RN 33369-24-3 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-N-hydroxy-1-methyl- (CA INDEX NAME)



RN 33369-25-4 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-(4-chlorobenzoyl)-N-[2-(diethylamino)ethyl]-1-methyl- (CA INDEX NAME)

L12 ANSWER 239 OF 240 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 33369-51-6 CAPLUS
CN 1H-Pyrrole-2-acetamide, 1-methyl-5-[4-methylbenzoyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

ACCESSION NUMBER: 1965:90798 CAPLUS
DOCUMENT NUMBER: 62:90798
ORIGINAL REFERENCE NO.: 62:16198e-h,16199a-h
TITLE: Indole acid amides
PATENT ASSIGNEE(S): Merck & Co., Inc.
SOURCE: 40 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6404781		19641102	NL 1964-4781	19640429
BE 647413			BE	
US 3285908			US	
PRIORITY APPLN. INFO.:			US	19630430

AB I showed antiinflammatory and analgesic properties. 25 g. 4-MeOC6H4NHNH2.HCl (II) (25 g.) and 20 g. AcCH2CHMeCO2Et (III) in 250 ml. 2N ethanolic HCl heated a few min. on a steam bath gave an exothermal reaction with NH4Cl separation and the mixture refluxed 30 min. to yield I (R = H, R1 = OMe, R2 = Me, R3 = OEt) (IV), b0.25 150-3° m. 58-5.5°. Similarly, 4-MeC6H4NHNH2.HCl and III gave the 5-Me analog of IV, m. 88-8.5°. A suspension of 2.3 g. 50% Nah in mineral oil and 250 ml. HCONMe2 stirred 20 min. under N and ice-cooled, 8.64 g. IV added, stirred 20 min., 8.6 g. 4-MeSC6H4COCl in 50 ml. HCONMe2 added dropwise in 30 min., and the ice-cooled mixture stirred 5 hrs. under N gave I (R = COC6H4SMe-4, R1 = OMe, R2 = Me, R3 = OEt). I(R = R2 = H, R1 =R3 = OMe) (V) gave the N-COC6H4Cl-4 analog (VI), m. 99-100°, after treatment with NaIl and 4-ClC6H4COCl. Similarly, the following I (R1 = OMe) were prepared (R, R2, R3, and m.p. given): COC6H4(SMe)Me-4,2, Me, OEt, --; COC6H4Cl-4, Me, OEt, --; COC6H4F-4, Me, OEt, --; COC6H4OMe-4, H, OH, 88-9°; COC6H4OMe-4, Me, OH, 65°; COC6H4Br-4, H, OMe, 106-7.5°; COC6H4NO2-4, H, OMe, 130-2°; COC6H4Cl-2, H, OMe, 91-3°; COC6H4Cl-3, H, OMe, 51-2°; COC6H4Ph-4, H, OMe, 101.5-3.0°; COC6H4OAc, H, OMe, 99-101°; 4-thiazolylcarboxy, H, OEt, 76-82°; 2-thenoyl, H, OEt, --; COC6H4Br-4, Me, tert-Bu, 103-5°; α-naphthoyl, H, OMe, --; COC6H4OCH2Ph-4, H, OMe, 116-18°; COC6H4OH-4, H, OMe, 98-9°; 2-thenoyl, H, OH, 62°; β-naphthoyl, H, OMe, 120-4° 5-chloro-2-thenoyl, H, OMe, --; COC6H4CF3-4, H, OH, 169-71°; COC6H3(OMe)2-2,6, H, OMe, 139.5-41°; COC6H3-Cl2-2,4, H, OMe, --. A solution 15 g. V and 0.2 g. Na in 60 ml. PhCH2OH was distilled to remove MeOH and excess PhCH2OH distilled (60°/2.5 mm.) to give 18.6 g. I (R = R2 = H, R1 = OMe, R3 = OCH2Ph) (VII), which with NaH and BzCl gave the N-Bz analog (VIII), m. 91-2°. VIII (1.5 g.) was reduced over Pd-C in the presence of 20 ml. AcOEt and 1 drop AcOH to yield I (R = Bz, R1 = OMe, R2 = H, R3 = OH) (IX), m. 172-3° (aqueous EtOH). To 22g. I(R = R2 = H, R1 = OMe, R3 = OH) (X) in 200 ml. tetrahydrofuran was added 10 g.

N,N-dicyclohexylcarbodiimide (XI), the mixt. kept 2 hrs. at room temp., the sepd. urea filtered off, and the filtrate evapd. in vacuo to give the anhydride of X, an oil, to which 25 ml. tert-BuOH and 0.3 g. fused ZnCl2 was added, and the mixt. refluxed 16 hrs. to give 93% I (R = R2 = H, R1 = OMe, R3 = OBu-tert) (XII), which gave its N-COC6H4.Cl-4 analog, m. 103-4°, with NaH and VI. The free acid m. 151°. I (R = H, R1 = OMe, R2 = Me, R3 = OH) (XIII) and XI gave the anhydride of XIII, oil, converted into the tert-Bu ester (XIV) of XIII, oil. The N-COC6H4SMe-4 analog of XIV, yellow oil, was pyrolyzed to give the N-COC6H4SMe-4 analog of XIII, m. 175-6° (aq. EtOH or C6H6). The N-COC6H4Cl-4 analog of XIV was converted into the free acid, m. 87-8° (C6H6-petr. ether). Isonicotinic acid, 4-HOC6H4NO2, and XI in tetrahydrofuran gave p-nitrophenyl isonicotinate (XV), m. 126-7° (C6H6). To 10.5 g. V in 100 ml. Me2NCHO at 0° under N was added 2.5 g. of an emulsion of 50% NaH in mineral oil, the mixt. stirred 30 min., 11 g. XV in 50 ml. Me2NCHO added, stirred 4 hrs. under N at 0° and overnight at room temp. Work-up gave the N-isonicotinoyl deriv. of V. CH2CH2CO2H (XVI) and 4-O2NC6H4NHNH2. HCl gave a hydrazone, m. 175-9°, which with fused ZnCl2 in EtOH refluxed 18 hrs. gave I (R = R2 = H, R1 = NO2, R3 = OH), m. 238° (CHCl3); Me ester (XVII) m. 132-40° (C6H6). XVII (3 g.) in 300 ml. anhyd. MeOH reduced with H over Raney Ni in an autoclave gave the 5-Nh2 analog (XVIII) of XVII, m. 144-5° (C6H6). XVIII (1 g.), 0.99 g. Br(CH2)4Br, and 0.975 g. anhyd. Na2CO3 was refluxed 6 hrs. under N to give I (R = R2 = H, R1 = pyrrolidino, R3 = OMe), m. 117-18° (C6H6-Skellysolve B), which was converted into its N-COC6H4Cl-4 analog, m. 62-4° (Et2O). The N-COC6H4Cl-4 analog (XIX) of XVII, m. 170-1°, and 37% aq. H2CO in dimethoxyethane contg. AcOH was reduced at room temp. with Raney Ni at 2.8 kg./cm.2 to give I (R = R2 = H, R1 = NO2, R3 = OMe), oil. Similar redn. of XIX and Ac2O in AcOEt gave I (R = COC6H4Cl-4, R1 = NHAc, R2 = H, R3 = OMe), m. 176-7° (C6H6-Et2O). I (R = R2 = H, R1 = NO2, R3 = OCH2Ph), m. 147-8°, was converted into its N-COC6H4Cl-4 analog, m. 166-7° (C6H6-Skellysolve B). Pd-C redn. of the NO2 group of I (R = COC6H4Cl-4, R1 = NO2, R2 = Me, R3 = OMe) gave the corresponding NH2 compd., which autoclaved with ethylene oxide gave I [R = COC6H4Cl-4, R1 = N(CH2CH2OH)2, R2 = Me, R3 = OMe] (XX). A soln. of 1 mole XX and 2 moles p-MeC6H4SO2Cl (XXI) in C5H5N stirred at 0° gave the 5-N(CH2CH2OSO2C6H4Me-4)2 analog of XX, which with MeNH2 in C6H6 kept 3 days at room temp. gave I (R = COC6H4Cl-4, R1 = 4-methyl-1-piperazinyl, R2 = H, R3 = OMe). I [R = COC6H4Cl-4, R1 = N(CH2CH2OH)2, R2 = H, R3 = OMe] (XXIII) and XXI gave the 5-morpholino analog of XXII. NCC6H4NHNH2 and XVI gave I (R = R2 = H, R1 = CN, R3 = OH), which with CH2N2 gave the Me ester (XXIII). Reductive amination of the N-COC6H4Cl-4 analog of XXIII in EtOH gave I (R = COC6H4Cl-4, R1 = CH2NH2, R2 = H, R3 = OMe), converted into its 5-CH2NMe2 deriv. with MeI. AcCH2CHEtCO2Et and II gave I (R = H, R1 = OMe, R2 = Et, R3 = OEt), from which the N-COC6H4SMe-4 analog was prepd. A mixt. of 500 ml. Et2O, 36.02 g. triphenylphosphonium bromide, and 94.36 ml. 1.1N BuLi was stirred under N; after 1 hr., 38 g. Et (2-methyl-5-methoxy 3-indolyl)glyoxylate in 160 ml. C6H6 and 500 ml. Et2O

was added, stirred 1 hr., and autoclaved at 65-70° 5 hrs. to give Et α-(2-methyl-5-methoxy-3-indolyl) acrylate which was converted with 4-O2NC6H4O2CPh into its N-Bz analog (XXIV). To CH2I2, Zn-Cu, and iodine in tetrahydrofuran was added XXIV, the mixt. refluxed 20 hrs., and worked up to give Et α-(1-benzoyl-2-methyl-5-methoxy-3-indolyl)cyclopropane carboxylate. Isobutyl chloroformate (0.0075 mole) was added to an ice-cooled mixt. of 0.0075 mole I (R = COC6H4Cl-4, R1 = OMe, R2 = H, R3 = OH) (XXV) and 0.0075 mole Et3N in 40 ml. 1,2-dimethoxyethane, kept under N, after 20 min. the whole filtered and 0.008 mole morpholine in 1,2-dimethoxyethane added to the cooled filtrate. The mixt. kept overnight and filtered to yield I (R = COC6H4Cl-4, R1 = OMe, R2 = H, R3 = morpholino) (XXVI), m. 162-3.5° (C6H6-petr. ether). Similarly, XXV gave with Me2NH, ethanolamine, PhCH2NH2, N,N-diethylethylenediamine, and benzylglycinate, resp., the N,N-dimethyl, 179.5-80.5°, N-β-hydroethoxy, m. 137-8° N-PhCH2, N-(β-N',N'-diethylaminoethyl), m. 110-11.5°, and N-carboxybenzyloxymethyl, m. 133-4.5° (XXVII) acetamides of XXV. I (R = COC6H4Cl-4, R1 = F, R2 = H, R3 = OH) with morpholine gave the 5-F analog of XXVI, m. 168-70° Redn. of XXVII (Pd-C) gave the corresponding N-carboxymethylacetamide, m. 152.5-54°.

IT 1568-30-5P, Indole-3-acetamide, 1-benzoyl-5-methoxy-2-methyl-
2854-21-9P, Glycine, N-[[1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]- 2854-34-4P, Indole-3-acetamide, 1-(p-chlorobenzoyl)-N-[2-(diethylamino)ethyl]-5-methoxy-2-methyl-
2878-86-6P, Indole-3-acetamide, 1-(p-chlorobenzoyl)-N-(2-hydroxyethyl)-5-methoxy-2-methyl-
3326-40-7P, Glycine, N-[[1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]-, benzyl ester
RL: PREP (Preparation)
(preparation of)

RN 1568-30-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-benzoyl-5-methoxy-2-methyl- (CA INDEX NAME)



RN 2854-21-9 CAPLUS
CN Glycine, N-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]- (CA INDEX NAME)



RN 2854-34-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-[2-(diethylamino)ethyl]-5-methoxy-2-methyl- (CA INDEX NAME)



RN 2878-86-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-(2-hydroxyethyl)-5-methoxy-2-methyl- (CA INDEX NAME)

L12 ANSWER 249 OF 249 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 3324-4G-7 CAPLUS
CN Glycine,
N-[[1-[4-chlorobenzoyl]-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]-
, phenylmethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)